MXPA04004018A - Metodos de separacion por exclusion para toxicidad de compuestos de prueba. - Google Patents

Metodos de separacion por exclusion para toxicidad de compuestos de prueba.

Info

Publication number
MXPA04004018A
MXPA04004018A MXPA04004018A MXPA04004018A MXPA04004018A MX PA04004018 A MXPA04004018 A MX PA04004018A MX PA04004018 A MXPA04004018 A MX PA04004018A MX PA04004018 A MXPA04004018 A MX PA04004018A MX PA04004018 A MXPA04004018 A MX PA04004018A
Authority
MX
Mexico
Prior art keywords
methods
test compounds
toxicity
screening
determining
Prior art date
Application number
MXPA04004018A
Other languages
English (en)
Inventor
K Durham Stephen
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MXPA04004018A publication Critical patent/MXPA04004018A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invencion se refiere a metodos de separacion por exclusion de candidatos a farmaco para efectos toxicos en celulas humanas. La invencion proporciona metodos para determinar la toxicidad idiosincratica de los compuestos de prueba.
MXPA04004018A 2001-10-31 2002-10-31 Metodos de separacion por exclusion para toxicidad de compuestos de prueba. MXPA04004018A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33650901P 2001-10-31 2001-10-31
PCT/US2002/034894 WO2003050297A1 (en) 2001-10-31 2002-10-31 Methods of screening for toxicity of test compounds

Publications (1)

Publication Number Publication Date
MXPA04004018A true MXPA04004018A (es) 2004-07-23

Family

ID=23316423

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04004018A MXPA04004018A (es) 2001-10-31 2002-10-31 Metodos de separacion por exclusion para toxicidad de compuestos de prueba.

Country Status (8)

Country Link
US (1) US7041501B2 (es)
EP (1) EP1446497A4 (es)
JP (1) JP2005511093A (es)
AU (1) AU2002364692B2 (es)
CA (1) CA2465262A1 (es)
IL (1) IL161300A0 (es)
MX (1) MXPA04004018A (es)
WO (1) WO2003050297A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759113B2 (en) * 1999-04-30 2010-07-20 The General Hospital Corporation Fabrication of tissue lamina using microfabricated two-dimensional molds
US7776021B2 (en) * 2000-04-28 2010-08-17 The Charles Stark Draper Laboratory Micromachined bilayer unit for filtration of small molecules
WO2004065616A2 (en) 2003-01-16 2004-08-05 The General Hospital Corporation Use of three-dimensional microfabricated tissue engineered systems for pharmacologic applications
EP1636351A4 (en) 2003-05-21 2007-04-04 Gen Hospital Corp MICROFABRICATED COMPOSITIONS AND METHOD FOR CONSTRUCTING TISSUES WITH MULTIPLE CELL TYPES
US7452678B2 (en) * 2003-06-24 2008-11-18 Bristol-Myers Squibb Company Identification of biomarkers for liver toxicity
US20050014217A1 (en) * 2003-07-18 2005-01-20 Cytokinetics, Inc. Predicting hepatotoxicity using cell based assays
US7235353B2 (en) * 2003-07-18 2007-06-26 Cytokinetics, Inc. Predicting hepatotoxicity using cell based assays
WO2007146203A1 (en) * 2006-06-08 2007-12-21 The University Of North Carolina At Chapel Hill Pulsing of bile compartments in sandwich-cultured hepatocytes
WO2012031057A1 (en) 2010-09-01 2012-03-08 Bristol-Myers Squibb Company Bms- 582949 for the treatment of resistant rheumatic disease
JP2017035081A (ja) * 2015-08-13 2017-02-16 サントリーホールディングス株式会社 動物細胞毒性又は抗酸化能の試験方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356806A (en) 1987-06-05 1994-10-18 The United States Of America As Represented By The Department Of Health And Human Services Immortalized human cell lines containing exogenous cytochrome P450
US5164313A (en) 1987-06-05 1992-11-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Recombinant vaccinia virus encoding cytochromes P-450
US5506131A (en) * 1987-06-05 1996-04-09 The United States Of America As Represented By The Department Of Health And Human Services Immortalized human cell lines containing exogenous cytochrome P450 genes
US5665589A (en) 1988-12-14 1997-09-09 The United States Of America As Represented By The Department Of Health And Human Services Human liver epithelial cell lines
AU621972B2 (en) 1988-12-14 1992-03-26 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Cell culture medium for human liver epithelial cell line
US5529920A (en) 1988-12-14 1996-06-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human liver epithelial cell line and culture media therefor
JPH0749923B2 (ja) * 1989-05-31 1995-05-31 大日本スクリーン製造株式会社 レーザ測長器のための単位変換装置
US5457187A (en) * 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
US5759782A (en) * 1995-06-07 1998-06-02 The United States Of America Cellular apoptosis susceptibility protein (CSP) and antisense CSP
US5869243A (en) 1996-03-05 1999-02-09 Rhode Island Hospital Immortalized hepatocytes
TW471968B (en) * 1999-08-25 2002-01-11 Committee On Chinese Medicine Solamargine pharmaceutical composition for killing cancer cells
US6852845B1 (en) * 1999-11-22 2005-02-08 Curagen Corporation Method of identifying toxic agents using NSAID-induced differential gene expression in liver
US7700822B2 (en) * 2002-07-12 2010-04-20 Cancer Research Technology Limited Modulation of cytochrome P450 reductase activity

Also Published As

Publication number Publication date
CA2465262A1 (en) 2003-06-19
EP1446497A1 (en) 2004-08-18
EP1446497A4 (en) 2004-12-29
US7041501B2 (en) 2006-05-09
WO2003050297A1 (en) 2003-06-19
US20030113708A1 (en) 2003-06-19
JP2005511093A (ja) 2005-04-28
AU2002364692A1 (en) 2003-06-23
AU2002364692B2 (en) 2006-11-23
IL161300A0 (en) 2004-09-27

Similar Documents

Publication Publication Date Title
ATE412891T1 (de) Verbessertes toxizität-screening verfahren
EP1700120A4 (en) MARKER FOR OPTICAL NEUROMYELITIS
BR0116452A (pt) Composto, composição farmacêutica, uso de um composto
EA200200530A1 (ru) Гетероциклические замещенные пиразолоны
ECSP034874A (es) Benzoilsulfonamidas y sulfonilbenzamidinas que se usan como agentes antitumorales
GB2451042A (en) Reagents and methods for using human embryonic stem cells to evaluate toxicity of pharmaceutical compounds and other chemicals
ATE349434T1 (de) Lactamderivaten zur verwendung als humane 11cby rezeptorantagonisten
EA200601554A1 (ru) Замещенные индол-о-глюкозиды
DE60226797D1 (de) Instrument zum Einbringen von Befestigungselementen für Transplantate
TW200505890A (en) Breast cancer-resistant protein inhibitor
NO20052794L (no) Antibakterielle indolonoksazolidinoner intermediater for fremstilling av disse og farmasoytiske prepareter inneholdende disse
ECSP045255A (es) Cumarinas utiles como biomarcadores
UY28348A1 (es) Compuestos novedosos
TR199901057T2 (es)
MXPA04004018A (es) Metodos de separacion por exclusion para toxicidad de compuestos de prueba.
ATE375978T1 (de) Benzoylsulfonamide als antitumor-mittel
MXPA04003755A (es) Endoprotesis vasculares.
PA8577701A1 (es) Polipeptido t20 pegilado
AU3392901A (en) Proteins
WO2005012901A3 (en) Method for measuring aromatase activity
WO2004045545A3 (en) Compositions and methods for the treatment of cancer, screening of putative anti-cancer compounds, and assessing cancer progression
BR0316544A (pt) Compostos calcilìticos
EP1436279A4 (en) CHEMICAL COMPOUNDS
DE60106947D1 (de) Oxindolderivate
EA200601030A1 (ru) 7α,17α-ЗАМЕЩЁННЫЕ 11β-ГАЛОГЕНОСТЕРОИДЫ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, ПРИМЕНЕНИЕ И ФАРМАЦЕВТИЧЕСКИЙ ПРЕПАРАТ НА ИХ ОСНОВЕ